| Dr Michael Anthony Glazeski, OD | |
|
2241 Central Ave, Alameda, CA 94501-4460 | |
| (510) 522-0377 | |
| Not Available |
| Full Name | Dr Michael Anthony Glazeski |
|---|---|
| Gender | Male |
| Speciality | Optometrist - Corneal And Contact Management |
| Location | 2241 Central Ave, Alameda, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093857864 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152WC0802X | Optometrist - Corneal And Contact Management | 06670TPL (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Anthony Glazeski, OD 42 Camelford Pl, Oakland, CA 94611-2556 Ph: (510) 522-0377 | Dr Michael Anthony Glazeski, OD 2241 Central Ave, Alameda, CA 94501-4460 Ph: (510) 522-0377 |
News Archive
Aspen Brook Consulting, Inc., announces the 2010 Bioprocess Management Summit. This event, occurring February 24th-26th, 2010 at The Canyons Hotel and Conference Center in Park City UT, has been designed as a forum where members of the bioprocess community gather annually to share their knowledge and experience in an effort to address challenges facing the biopharmaceutical industry.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee has recommended that the FDA grant ocriplasmin approval for the treatment of symptomatic Vitreomacular Adhesion.
The U.S. Food and Drug Administration has approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).
While working with parents of children with attention deficit hyperactivity disorder (ADHD) at the University at Buffalo, Gregory A. Fabiano noticed something was missing: the fathers.
Merck KGaA today announced that the first patient has been enrolled in its global Phase III clinical study, START (Stimulating Targeted Antigenic Responses To NSCLC), assessing the efficacy and safety of Stimuvax (BLP25 liposome vaccine) as a potential treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC).
› Verified 6 days ago
Dr. Daniel Chin, DOCTOR OF OPTOMETRY Optometrist Medicare: May Accept Medicare Assignments Practice Location: 1409 (half) Park Street, Alameda, CA 94501 Phone: 510-523-1344 Fax: 510-523-2089 | |
Eyewise Optometry Optometrist Medicare: Medicare Enrolled Practice Location: 2651 Blanding Ave, Ste B, Alameda, CA 94501 Phone: 510-710-1625 | |
Dr. Shelly Yvon Sheppard, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 1801 Santa Clara Ave, Alameda, CA 94501 Phone: 510-521-2015 Fax: 510-521-2123 | |
Christopher P. Young Od, Inc. Optometrist Medicare: Medicare Enrolled Practice Location: 847 Marina Village Pkwy, Alameda, CA 94501 Phone: 510-337-7970 | |
Michael F Britt, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 887a Island Dr, Alameda, CA 94502 Phone: 510-814-7268 Fax: 510-814-0134 | |
Milan An, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2236 Southshore Center, Alameda, CA 94501 Phone: 510-521-2734 |